We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Name | Symbol | Market | Type |
|---|---|---|---|
| AstraZeneca PLC | NASDAQ:AZN | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.22 | 0.29% | 77.26 | 77.25 | 77.26 | 77.525 | 76.87 | 76.94 | 1,891,784 | 18:20:15 |
From May 2021 to May 2024
By Kyle Morris
AstraZeneca PLC said Thursday that it has signed a collaboration agreement with Scorpion Therapeutics for the development and commercialization of treatments for hard-to-target cancer proteins in oncology.
The pharmaceutical giant said Scorpion will receive an upfront cash payment of $75 million, and retain the potential for additional success-based payments and tiered royalties on net sales.
The partnership will focus on transcription-factors proteins and combine Scorpion's discovery platform with AstraZeneca's development and commercialization capabilities in precision medicines for cancer treatment.
Transcription-factors proteins control gene expression and can regulate cellular processes such as cell growth and survival, it said. Many have been identified as important targets for new cancer treatments and as disease drivers, but drug treatment was previously considered as not possible using conventional drug discovery approaches, it added.
Write to Kyle Morris at kyle.morris@dowjones.com
(END) Dow Jones Newswires
January 13, 2022 02:42 ET (07:42 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year AstraZeneca Chart |
1 Month AstraZeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
